ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Revenue
ABL Bio Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Revenue
â‚©33.4B
|
CAGR 3-Years
84%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
![]() |
Celltrion Inc
KRX:068270
|
Revenue
â‚©2.9T
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
23%
|
|
![]() |
SK Bioscience Co Ltd
KRX:302440
|
Revenue
â‚©267.5B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Revenue
â‚©363.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Revenue
â‚©317B
|
CAGR 3-Years
30%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
![]() |
Alteogen Inc
KOSDAQ:196170
|
Revenue
â‚©74.4B
|
CAGR 3-Years
36%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Revenue?
Revenue
33.4B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Revenue amounts to 33.4B KRW.
What is ABL Bio Inc's Revenue growth rate?
Revenue CAGR 5Y
53%
Over the last year, the Revenue growth was -49%. The average annual Revenue growth rates for ABL Bio Inc have been 84% over the past three years , 53% over the past five years .